Updated:
Artivion
Artivion is a publicly traded aortic-medical-device company founded in 1984, led by CEO J.
Artivion
Artivion was founded in 1984 and is headquartered in Kennesaw, Georgia, with additional offices in Germany, Thailand, and Singapore. J. Patrick Mackin has served as Chairman, President, and CEO since 2014, bringing over 30 years of medical device experience from Medtronic and Genzyme. The firm does not disclose a single-family-office wealth origin, operating instead as a publicly traded entity. The company's portfolio spans multiple device categories: mechanical and tissue heart valves (ON-X®), stent graft systems for aortic arch repair (NEXUS®, AMDS™), surgical adhesives (BIOGLUE®), and cryopreserved allografts (CRYOVALVE®). Artivion continuously invests in clinical trials and regulatory approvals — in December 2024 the FDA granted a Humanitarian Device Exemption for the AMDS Hybrid Prosthesis for acute DeBakey Type I dissections. The firm sells in North America, Europe, Asia Pacific, Latin America, and the Middle East. Artivion employs over 1,600 people globally, with manufacturing facilities in Georgia, Texas, and Hechingen, Germany. In May 2026 the company completed the acquisition of Endospan Ltd., a developer of the NEXUS® Aortic Arch System. The firm also conducts philanthropic outreach, having supported medical mission trips to 25+ countries and donated over 500 cardiac allografts and valves. As a publicly traded company (NYSE: AORT), Artivion operates under regulatory oversight from the FDA and other global health authorities. This structure distinguishes it from privately held medical device firms and family offices, requiring public financial disclosures and formal board governance.
General information
Firm type
Asset Manager
Year founded
1984
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Kennesaw
Corporate office
1655 Roberts Blvd., NW Kennesaw, GA 30144, United States
Additional offices
Hechingen, Germany · Bangkok, Thailand · Singapore
Principals
J. Patrick Mackin
Chairman, President, and Chief Executive Officer
Lance Berry
Executive Vice President, Chief Operating Officer, and Chief Financial Officer
John E. Davis
Chief Commercial Officer
Jean F. Holloway
Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
Simona Zannetti
Senior Vice President of Clinical Research and Chief Medical Officer
Jason Asper
Senior Vice President and Chief Strategy and Digital Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Artivion?
J. Patrick Mackin serves as Chairman, President, and CEO, leading corporate strategy and capital allocation. Lance Berry, appointed EVP, COO, and CFO in December 2023, oversees financial operations. Major M&A and R&D decisions are made by the executive team and board.
How does Artivion source proprietary technology?
Artivion develops technology internally through its R&D team and supplements with acquisitions. The May 2026 acquisition of Endospan Ltd. added the NEXUS® Aortic Arch System. The company also partners with surgeons for clinical trials such as the PERSEVERE study for the AMDS Hybrid Prosthesis.
Is Artivion structured as a family office or a public company?
Artivion is a publicly traded corporation listed on the NYSE under ticker AORT. It operates with a board of directors and files quarterly and annual reports with the SEC. It does not function as a family office.
Does Artivion participate in fund commitments or only direct operations?
As a medical device company, Artivion does not make external fund commitments. Its capital is deployed into internal R&D, manufacturing, clinical trials, and strategic acquisitions.
What investment stages does Artivion typically target?
Artivion targets later-stage commercial medical devices, often acquiring or developing products that already have regulatory clearance or are in pivotal trials. Examples include the AMDS Hybrid Prosthesis and On-X heart valves.
Which sectors does Artivion explicitly avoid?
Artivion focuses exclusively on aortic and cardiac surgery technologies. It does not pursue non-surgical therapies, pharmaceutical drugs, or general healthcare services outside its core aortic device domain.
How is Artivion related to Endospan Ltd.?
Artivion completed the acquisition of Endospan Ltd. in May 2026. Endospan was a long-standing partner and developer of the NEXUS® Aortic Arch System, which Artivion now fully owns and integrates into its stent graft portfolio.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: